Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFISOXAZOLE.
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFISOXAZOLE.
SODIUM SULFACETAMIDE vs SULFISOXAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Sulfisoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the synthesis of dihydrofolic acid and ultimately inhibiting bacterial folate synthesis and DNA replication.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
1-2 g orally once, then 500 mg-1 g orally every 4-6 hours; maximum 6 g/day.
None Documented
None Documented
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
Clinical Note
moderateSulfisoxazole + Gatifloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfisoxazole + Rosoxacin
"Sulfisoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfisoxazole + Trovafloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfisoxazole + Nalidixic acid
Terminal elimination half-life is 5-7 hours in adults with normal renal function; prolonged to 12-20 hours in renal impairment (CrCl <30 mL/min).
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal excretion accounts for 70-85% of elimination, predominantly as unchanged drug (30-50%) and the N4-acetyl metabolite (15-30%). Biliary/fecal excretion is minimal (<5%).
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfisoxazole may increase the hypoglycemic activities of Nalidixic acid."